Biliverdin Reductase inhibitors did not improve severe unconjugated hyperbilirubinemia in vivo

We aimed to identify potent biliverdin reductase (BVRA) inhibitors as a novel concept for the treatment of severe unconjugated hyperbilirubinemia. 1280 FDA-approved compounds were screened in vitro for their ability to inhibit human and rat BVRA activity and 26 compounds were identified as BVRA in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Sci Rep
Autores principales: van Dijk, Remco, Aronson, Sem J., de Waart, Dirk R., van de Graaf, Stan F., Duijst, Suzanne, Seppen, Jurgen, Elferink, Ronald Oude, Beuers, Ulrich, Bosma, Piter J.
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5431759/
https://ncbi.nlm.nih.gov/pubmed/28490767
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-01602-w
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares